Evidence map›Paper›PMID 41836405›Full record

ArticleFrontiers in immunology2026

Unravelling the complexity of the interactions among VACCIMEL, BCG and blood monocytes.

Erika Schwab, Brenda Carles, Alicia Inés Bravo, María Victoria Echenique, Agustina De Franc, Mariano Guillermo Bonanno, María Marcela Barrio, José Mordoh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Erika SchwabFacultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
Brenda CarlesCentro de Investigaciones Oncológicas-Fundación Cáncer (FUCA), Buenos Aires, Argentina.
Alicia Inés BravoCentro de Investigaciones Oncológicas-Fundación Cáncer (FUCA), Buenos Aires, Argentina.
María Victoria EcheniqueCentro de Investigaciones Oncológicas-Fundación Cáncer (FUCA), Buenos Aires, Argentina.
Agustina De FrancLANAIS-MIE, Instituto de Biología Celular y Neurociencia Prof. E. De Robertis, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Mariano Guillermo BonannoHospital Interzonal General de Agudos (HIGA) Eva Perón, San Martín, Argentina.
María Marcela BarrioCentro de Investigaciones Oncológicas-Fundación Cáncer (FUCA), Buenos Aires, Argentina.
José MordohCentro de Investigaciones Oncológicas-Fundación Cáncer (FUCA), Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VACCIMEL is an immunotherapeutic adjuvant treatment for high-risk cutaneous melanoma. It consists of 13 intradermal injections of four irradiated melanoma cell lines co-adjuvated with BCG and GM-CSF. VACCIMEL prolongs distant metastases-free survival and it induces T lymphocytes reactive against melanoma differentiation antigens, cancer testis antigens, and neoantigens. In this paper, we have studied

Indexed as

BCG VaccineCancer VaccinesMelanomaMonocytesMycobacterium bovisAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorCross-PrimingGranulocyte-Macrophage Colony-Stimulating FactorHumansInterleukin-10PhagocytosisAntigens, NeoplasmBCG VaccineCancer VaccinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-10BCGcutaneous melanomaimmunotherapyinnate immune cellsmonocytesphagocytosis

Identifiers

PMID41836405
PMCPMC12979123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.